Press Releases
Our latest happenings and recent highlights.
For media inquiries, please contact: ken.harris@omniabio.com Phone: +1-323-420-7766 (cell)
Featured
November 20, 2024 (Toronto, Ontario) – LineaBio, a cell line company, today announced it has submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its flagship unmodified, off-the-shelf, Good Manufacturing Practices (GMP)-compliant induced pluripotent stem cell (iPSC) line, Linea 1.LineaBio was launched in...
November 20, 2024 (Toronto, Ontario) – LineaBio, a cell line company, today announced it has submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its flagship unmodified, off-the-shelf,...
The site will add state-of-the-art CGT capacity and employ artificial intelligence and automation to achieve critical product supply efficiencies for North American and global biotherapy clients.Hamilton, ON., October 17, 2024 – Today OmniaBio Inc. will announce...
CDMO collaboration propels cell replacement therapy targeting Duchenne muscular dystrophy forward, with consequences for the role of AI in cell therapy. September 9, 2024 (BOSTON, MA and HAMILTON, Ontario) – Somite Therapeutics, a tech-bio company harnessing big...
CCRM and OmniaBio spin-off provides high-quality iPSC lines that expedite time to GMP by 12 months and reduce cell line development costs by up to 60%. July 30, 2024 (Toronto, Ontario) – LineaBio, a cell line...
June 12, 2024 (Hamilton, Ontario) – OmniaBio Inc. is pleased to announce the appointment of Kenneth (Ken) L. Harris as its Chief Strategy Officer and Head of Artificial Intelligence (AI), strengthening its mandate of bringing...
15 New projects underway to build world leading advanced manufacturing capabilities in Canada.TORONTO, ON, February 8, 2024 - NGen has announced over $32.3 million in Global Innovation Cluster funding for 15 new advanced manufacturing projects....